NCT04504448View on ClinicalTrials.gov

A Study of HNC664 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 11, 2020

Primary Completion Date

July 13, 2021

Study Completion Date

July 13, 2021

Conditions
Healthy
Interventions
DRUG

HNC664 capsules Single dose

HNC664 capsules,single ascending doses Single dose, PO,starting dose of 40mg escalating up to 500mg

DRUG

HNC664 placebos Single dose

HNC664 placebos single ascending doses,PO,Single dose, matching placebo

DRUG

HNC664 capsules FED

HNC664 capsules,single doses Single dose, PO,food effect（dosage will be based on data from SAD cohorts and decided by the IDRC）

Trial Locations (1)

21201

Pharmaron, Baltimore

All Listed Sponsors
lead

Guangzhou Henovcom Bioscience Co. Ltd.

INDUSTRY

NCT04504448 - A Study of HNC664 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics | Biotech Hunter | Biotech Hunter